Results 151 to 156 of about 681,398 (156)

Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020
Rolf W Sparidans, Alfred H Schinkel, Jos Beijnen   +2 more
exaly  

Larotrectinib for the treatment of TRK fusion solid tumors

Expert Review of Anticancer Therapy, 2019
Douglas S Hawkins, Theodore W Laetsch
exaly  

Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

ACS Medicinal Chemistry Letters, 2012
H Martin Seidel, Andreas Kreusch, Nanxin Li   +2 more
exaly  

HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, Trk, and morphological differentiation with fatal outcome in PC12 cells

Brain Research, 2000
Tatsuro Mutoh, Masaru Kuriyama, Hiroto Nakagawa   +2 more
exaly  

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model

Cancer Letters, 2016
Suzanne P MacFarland, Venkatadri Kolla, Garrett M Brodeur   +2 more
exaly  

Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update

Expert Opinion on Therapeutic Patents
Brent Page, Ralf Schirrmacher, Justin J Bailey   +2 more
exaly